Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial
Jolien de Jager, Adriaan Kooy, Philippe Lehert, Michiel G Wulffele, Jan van der Kolk, Daniel Bets, Joop Verburg, Ab JM Donker, Coen DA Stehouwer
BMJ | BMJ PUBLISHING GROUP | Published : 2010
Hyperinsulinaemia: the Outcome of its Metabolic Effects (HOME) trial was supported by grants from Altana, Lifescan, Merck Sante, Merck Sharp & Dohme, and Novo Nordisk. The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and all authors want to declare: (1) Financial support for the submitted work from Merck Sharp & Dohme. All authors also declare: (2) No financial relationships with commercial entities that might have an interest in the submitted work; (3) No spouses, partners, or children with relationships with commercial entities that might have an interest in the submitted work; and (4) No non-financial interests that may be relevant to the submitted work.